Conference Coverage
Conference Coverage
Talk early to patients with high-risk AML about end-of-life decisions
With nearly 40% of AML patients unable to take part in their own final code discussions, families struggle to guess what their loved ones would...
Conference Coverage
Myeloid patients respond robustly to Moderna COVID vaccine
Among 46 patients, nearly all seroconverted after second shot.
Conference Coverage
‘Outstanding data’: Mosunetuzumab in r/r follicular lymphoma
If approved by the FDA, mosunetuzumab has the potential to be a first-in-class CD20xCD3 T-cell engaging bispecific antibody in non-Hodgkin...
Conference Coverage
For leukemias, COVID-19 death risks tied to poor prognoses, ICU deferrals
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.
Conference Coverage
Beta-thalassemia gene therapy achieves lasting transfusion independence
“Seeing the restoration of iron metabolism, it really takes us a step closer to really thinking the term ‘cure’ might truly apply.”
Conference Coverage
‘Remarkable’ results with CAR T cells could make chemo obsolete
“It’s really remarkable that the results are so far in favor of the CAR T-cell therapy that I think it’s inevitable that this will become the...
Conference Coverage
Liver cancer risk lingers even after HCV eradication
Not having a sustained viral response was associated with a more than sevenfold higher risk for liver cancer in a multicenter study.
Conference Coverage
Genomic instability varies between breast cancer subtypes
Personalized medicine could be a step closer with the discovery that TNBC and ER+ breast cancers should have different genomic instability...
Conference Coverage
Ongoing HER2 breast cancer therapy may cost an additional $68,000 per patient
A Canadian study suggests that significant increases in cost per patient can be expected if funding policies don’t evolve to meet treatment needs...
Conference Coverage
1 in 7 breast cancers are overdiagnosed
The model takes into account indolent tumors and estimates one in seven screen-detected cancers will be overdiagnosed with biennial screening.
Conference Coverage
Vitamin D counters bone density loss with aromatase inhibitors
Researchers found no difference in bone mineral decline among breast cancer patients treated with aromatase inhibitors and those treated with...